PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2019
Filed with the SEC on Sep 13, 2019 and accepted by EDGAR at Sep 13, 2019, 17:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-05-01 to 2019-07-31 | $0 | us-gaap:Revenues |
| Research and development | 3 months2019-05-01 to 2019-07-31 | $72.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-05-01 to 2019-07-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-05-01 to 2019-07-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-05-01 to 2019-07-31 | −$1.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-05-01 to 2019-07-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2019-05-01 to 2019-07-31 | 1,210,305,834 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-05-01 to 2019-07-31 | −$763.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-07-31 | $327.8k | us-gaap:Cash |
| Current assets | At period end2019-07-31 | $477.0k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-07-31 | $5.6m | us-gaap:Assets |
| Current liabilities | At period end2019-07-31 | $606.6k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-07-31 | $606.6k | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-07-31 | $5.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-19-002926. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.